| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
4 companies
Kevin Rakin is Director at QSI and has filed Form 4s across 4 companies. Kevin Rakin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.2M at current prices.
Historically, Kevin Rakin's trades have earned a strong insider score of 77/100 across 5 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +53.5%.
The biggest single holding is QSI (~$1.6M) as Director. The QSI filings lean toward selling, a net 89,000 shares.
Kevin Rakin has 39 Form 4 filings on record from June 2015 to June 2026, across 4 companies: Director, 10% Owner at Elutia (ELUT), 2024–2026; Director at Quantum-Si (QSI), 2021–2026; Director at Oramed Pharmaceuticals (ORMP), 2016–2022, and 1 more.
The 67 reported transactions were 25 option or other derivative awards, 11 stock awards, 9 option exercises and 5 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $100K and 3 sales worth about $728K.
The largest open-market purchase was 70,000 shares of ELUT at an average $1.06 on January 30, 2026, about $74K.
The largest open-market sale was 21,100 shares of ORMP at an average $20.99 on September 16, 2021, about $443K. Twelve months later ORMP was down 63%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | ELUT Elutia Inc. | Director, 10% Owner | Buy | 70,000 | $1.06 | $74,200.00 | +55.5% | -2.9% | - | |
| Dec 17, 2025 | ELUT Elutia Inc. | Director, 10% Owner | Buy | 50,000 | $0.52 | $25,995.00 | +18.4% | +115.8% | - | |
| Dec 15, 2022 | QSI Quantum-Si Inc | Director | Sell | 89,000 | $2.15 | $191,234.30 | -4.7% | -17.7% | -20.9% | |
| Mar 21, 2022 | ORMP Oramed Pharmaceuticals Inc. | Director | Sell | 10,000 | $9.41 | $94,096.00 | -17.6% | -55.0% | -76.4% | |
| Sep 16, 2021 | ORMP Oramed Pharmaceuticals Inc. | Director | Sell | 21,100 | $20.99 | $442,829.92 | -27.0% | -27.7% | -63.2% | |
| Oct 10, 2018 | OCGN Ocugen, Inc. | Director | Buy | 230,768 | $0.00 | - | +1,560% | - | - |